Abstract:The outcome for older or unfit patients with acute myeloid leukaemia (AML) is usually dismal. Therapeutic options for these patients are limited in clinical practice.1, 2 Venetoclax (VEN) plus azacitidine (hereafter, VA regimen) have shown promising results in these AML patients, achieving CR/CRi in approximately 66%.3 However, acquired VEN resistance was the major obstacle for the maintenance of long-term remission in VEN sensitive patients.4 Since reconstructed pre-existing dominant mutations were the main contribution to acquired VEN resistance,5 combination VEN with chemotherapy may be a potential strategy to prevent acquired VEN resistance and even improve CR/CRi in AML. Recently, two clinical trials have demonstrated that VEN combined with intensive or lower intensive chemotherapy was a tolerable and promising regimen in fit patients with AML, with especially a CR/CRi rate of 82%–94%.6, 7 Herein, we demonstrated that chemotherapeutic agent low-dose cytarabine (LDAC) combined with VA regimen (referred as VAA regimen) offered a therapeutic advantage for AML cells with resistant or sensitive to VEN in vitro. Furthermore, we evaluated the anti-leukaemia activity of VAA regimen in older or unfit patients with AML in our routine clinical practice. The VEN-sensitive AML cells MV4-11 (IC50 = 4.506 nM) and VEN-resistant AML cells THP-1 (IC50 = 738.4 nM; Figure S1A) were used to evaluate whether the combination treatment of LDAC plus VA regimen performed robust synergistic killing in AML cells. Cell viability was determined by the CCK-8 assay. As shown in Figure 1A, VAA regimen enhanced the inhibitions of both cell lines compared with all single- or two-drug compositions. To further confirm the results, the apoptosis of both cell lines following with single-, two-drug or tri-drug combination were further tested by flow cytometry (FCM). Consistent with the result of the CCK-8 assay, the highest apoptosis rate was observed in VAA group in both AML cell lines (Figure 1B). However, the cell cycle distribution of both cell lines, as determined by FCM, did not show any significant cell cycle arrest in the VAA group (data not shown). These results collectively demonstrate that the addition of LDAC to VA regimen resulted in robust synergistic killing in both VEN-sensitive and -resistant AML cells. Subsequently, we validated the anti-leukaemia activity in routine clinical practice. To avoid the overlapping effects of VEN, azacitidine and LDAC on marrow suppression, we adopted a conservative study design. All patients were hospitalized for tumour lysis syndrome (LTS) evaluation and received LTS prophylaxis during the 3 days of VEN ramp-up. VEN dosing began at 100 mg on day 1, 200 mg on day 2, 400 mg on days 3 through 14 every 28 days for AML, while 400 mg on days 3 through 10 every 28 days for MDS derived AML. Azacitidine was administered at a dose of 75 mg/m2 of body-surface area, subcutaneously, on days 1 through 7 every 28 days. LDAC (10 mg/m2) was administered by subcutaneous injection twice daily on days 1–10 every 28 days. From 1 January 2021 to 30 June 2021, 12 patients with AML who were 65 years and older or unfit for intensive chemotherapy were consecutively allocated to VAA regimen treatment. Table 1 summarizes the patients and their clinical information. The median age of the patients was 65 years (range, 48–75 years) and 10 patients were over 65 years old. Seven patients had de novo AML, including 4 with relapsed AML and 3 with newly diagnosed AML. The other 5 patients had secondary AML transformed from myelodysplastic syndrome (MDS). All patients had mutation profile according to next-generation sequence (NGS) and analysis, including mutations in TP53, FLT3-ITD, FLT3-TKD, IDH1, IDH2, DNMT3A, CEBPAsingle, TET2, ASXL1, RUNX1, EP300, WT1, NRAS, KRAS, GATA, JAK2, EZH2, CROCC, ETV6, BCOR, TTN, BORO1, AR1D1B, PMRM1, EPPK1, CBL, PML and SRSF2. Additionally, 4 patients (3 with relapsed AML and 1 with MDS-derived AML) had previously received VEN-based regimen treatment. After one course of VAA regimen, 10 patients (83.3%) achieved CR, 1 patient (8.3%) achieved CRi and 1 patient (8.3%) achieved partial remission (PR). In the CR/CRi patients, multiparameter flow-cytometry based evaluation of minimal residual disease (MRD) negativity was attained in 8 (72.7%) patients. With a median follow-up of 15.2 months, 4 patients are still in remission, 1 patient relapsed and 7 patients died (3 MDS-derived AML, 3 relapsed AML and 1 primary AML). Median OS and median PFS in all 12 patients were 15.3 months (95%CI, 11.5 to 19.0) and 10.8 months (95%CI, 3.2 to 18.4), respectively. In subgroup analysis, median OS was not reached in primary AML, with better results compared to the other two groups, which were 13.8 months (95%CI, 4.6–23.1) in relapsed/refractory (R/R) AML and 16.1 months (95%CI, 14.2–18.1) in MDS-derived AML. The median PFS was 7.2 months (95% CI, 0 to 15.4) in R/R AML, 14.2 months (95% CI, NE to NE) in MDS-derived AML and 9.3 months (95% CI, 1.7–18.4) in primary AML (Figure 1C, Figure S1B). Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Common AEs are summarized in supplementary Table S1: during cycle 1 induction therapy, no Grade 5 events or TLS were recorded. Grade 3/4 of neutropenia and thrombocytopenia were observed in all 12 patients. Febrile neutropenia occurred in 10 patients (83.3%). The duration of neutrophil below 1 × 109/L was 21 days (range, 13–25), and platelets below 50 × 109/L was 23 days (range, 13–30), showing faster haematologic recovery than our previous data of VEN plus azacitidine (VEN dosing began at 100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 through 28 every 28 days; azacitidine at a dose of 75 mg/m2 of body-surface area, subcutaneously, on days 1 through 7 every 28 days) for R/R AML.8 The most common non-haematologic AEs were fatigue (58.3%), nausea (58.3%), vomiting (41.7%), constipation (41.7%) and diarrhoea (25%). Except for 1 patient with grade 3 sepsis and 3 patients with grade 3 pneumonia, no other grade 3/4 non-haematologic toxicity was observed. In all patients, the median hospital stay was 26 days (range, 20–36) during the first cycle. To our best knowledge, this is the first study to show the tolerability and efficacy of combining VA regimen with chemotherapeutic agent LDAC in older or unfit patients with AML. No cases of TLS or early death were recorded. The median time of neutrophil and platelets recovery was significantly shorter than our centre data of VA regimen for R/R AML.9 The ORR was 91.7%, including 83.3% CR and 8.3% CRi. Eight of 11 responders (72.7%) achieved MRD negative. Compared to previous outcomes of VEN plus intensive or lower intensive chemotherapy for AML,6, 7 VAA regimen represents a promising option for AML treatment. There are some limitations in this study, such as small sample size, short duration of follow-up, retrospective nature of analyses and lack of a comparative cohort. Nevertheless, this case series strongly indicate that the VAA regimen induced high response rates and was well-tolerated in AML patients. We have initiated prospective multicentre clinical trials to further evaluate the efficacy and safety of VAA regimen in R/R AML and MDS-derived AML (ChiCTR2100051119, ChiCTR2100051018). HTM and JJ designed the study. LSY and YL collected data and wrote the main manuscript. ZPL and YL designed and performed the experiments. LSY, LZ and LPM performed the tables. YLZ, JHW and CH reviewed the manuscript. All authors participated in the drafting of the manuscript and approved its final. Not applicable. The research was supported by the Natural Science Foundation of Zhejiang Province (Grant No. LZ23H080002) and the National Natural Science Foundation of China (Grant No. 81873451). The authors declare that they have no competing interests. Not applicable. All patients provided written informed consent. All data generated or analysed during this study are included in this published article and its supplementary information files. Figure S1. Table S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Venetoclax Plus Azacitidine and LDAC Induced High Response Rates in Acute Myeloid Leukaemia in Routine Clinical Practice

Venetoclax Plus Cytarabine and Azacitidine in Relapsed/Refractory AML: an Open-Label, Single-arm, Phase 2 Study.

Efficacy and Safety of Venetoclax in Combination with Cytarabine and Azacitidine (VAA) in Relapsed/refractory Acute Myeloid Leukemia: an Open-Label, Single-Arm, Phase II Study.

Venetoclax Plus Daunorubicin and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia Patients: A Propensity Score-Matched Analysis

15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

Venetoclax Plus “3+7” Chemotherapy As the First-Line Therapy for Adult Patients with Acute Myeloid Leukemia

Efficacy and Safety Analysis of Venetoclax Combined with Azacitidine in Real-World Treatment of Patients with AML

Venetoclax Plus 3+7 Daunorubicin and Cytarabine Chemotherapy As First-Line Treatment for Adults with Acute Myeloid Leukaemia: a Multicentre, Single-Arm, Phase 2 Trial

Venetoclax for Arsenic-Resistant Acute Promyelocytic Leukaemia

Safety and Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single Institution Experience

Single-institution Experience of Venetoclax Combined with Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients

P584: VENETOCLAX PLUS HOMOHARRINGTONINE-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKAEMIA: A MULTICENTRE, SINGLE-ARM, PHASE 2 TRIAL

Low‐dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia

Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia

Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis by the ABC-14 Collaboration Group

AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A

Comparison of Safety and Efficacy Between Venetoclax Combined with CAG (cytarabine, Aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML

Efficacy of Venetoclax and Azacitidine Based Therapy in Favorable-Risk Unfit Acute Myeloid Leukemia: a Real-World Study

Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia